Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab

被引:45
|
作者
Genant, Harry K. [1 ,2 ]
Libanati, Cesar [3 ]
Engelke, Klaus [4 ,5 ]
Zanchetta, Jose R. [6 ]
Hoiseth, Arne [7 ]
Yuen, Chui Kin [8 ]
Stonkus, Sigtas [9 ]
Bolognese, Michael A. [10 ]
Franek, Edward [11 ,12 ]
Fuerst, Thomas [13 ]
Radcliffe, Hoi-Shen [14 ]
McClung, Michael R. [15 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Synarc Inc, San Francisco, CA 94105 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Univ Erlangen Nurnberg, Inst Med Phys, D-91052 Erlangen, Germany
[5] Synarc Inc, Hamburg, Germany
[6] Inst Invest Metab, Buenos Aires, DF, Argentina
[7] Curato Rentgen, Oslo, Norway
[8] SIGMA Canadian Menopause Soc, Vancouver, BC V6H 1E5, Canada
[9] Klaipeda Univ Hosp, LT-92228 Klaipeda, Lithuania
[10] Bethesda Hlth Res, Bethesda, MD 20879 USA
[11] Cent Clin Hosp MSWiA, PL-02507 Warsaw, Poland
[12] Polish Acad Sci, Med Res Ctr, PL-02106 Warsaw, Poland
[13] Synarc Inc, Newark, CA 94560 USA
[14] Amgen Ltd, Cambridge CB4 OWD, England
[15] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
关键词
Bone mineral density; Bone mineral content; Denosumab; Hip; Osteoporosis; Quantitative computed tomography; QUANTITATIVE COMPUTED-TOMOGRAPHY; BONE-MINERAL DENSITY; OSTEOPROTEGERIN LIGAND; NONINVASIVE ASSESSMENT; FRACTURES; TURNOVER; STRENGTH; ALENDRONATE; PHASE-2; AMG-162;
D O I
10.1016/j.bone.2013.07.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the FREEDOM study, denosumab treatment (60 mg every 6 months) decreased bone resorption, increased bone mineral density (BMD), and reduced new vertebral, nonvertebral, and hip fractures over 36 months in postmenopausal women with osteoporosis. In a subset of these women, hip quantitative computed tomography (QCT) was performed at baseline and months 12, 24, and 36. These scans were analyzed using Medical Image Analysis Framework (MIAF) software, which allowed assessment of total hip integral, trabecular, subcortical, and cortical compartments; the cortical compartment was further divided into 2 areas of interest (outer and inner cortex). This substudy reports changes in BMD and bone mineral content (BMC) from baseline and compared placebo with denosumab over 36 months of treatment (placebo N = 26; denosumab N = 36). Denosumab treatment resulted in significant improvements in total hip integral volumetric BMD (vBMD) and BMC from baseline at each time point. At month 36, the mean percentage increase from baseline in total hip integral vBMD and BMC was 6.4% and 4.8%, respectively (both p < 0.0001). These gains were accounted for by significant increases in vBMD and BMC in the trabecular, subcortical, and cortical compartments. In the placebo group, total hip integral vBMD and BMC decreased at month 36 from baseline by -1.5% and -2.6%, respectively (both p < 0.05). The differences between denosumab and placebo were also significant at months 12, 24, and 36 for integral, trabecular, subcortical, and cortical vBMD and BMC (all p < 0.05 to <0.0001). While the largest percentage differences occurred in trabecular vBMD and BMC, the largest absolute differences occurred in cortical vBMD and BMC. In summary, denosumab significantly improved both vBMD and BMC from baseline and placebo, assessed by QCT MIAF, in the integral, trabecular, subcortical, and cortical hip compartments, all of which are relevant to bone strength. (C) 2013 The Authors. Published by Elsevier Inc All rights reserved.
引用
收藏
页码:482 / 488
页数:7
相关论文
共 50 条
  • [1] Denosumab Densitometric Changes Assessed by Quantitative Computed Tomography at the Spine and Hip in Postmenopausal Women With Osteoporosis
    McClung, Michael R.
    Zanchetta, Jose R.
    Hoiseth, Arne
    Kendler, David L.
    Yuen, Chui Kin
    Brown, Jacques P.
    Stonkus, Sigitas
    Goemaere, Stefan
    Recknor, Chris
    Woodson, Grattan C.
    Bolognese, Michael A.
    Franek, Edward
    Brandi, Maria Luisa
    Wang, Andrea
    Libanatil, Cesar
    JOURNAL OF CLINICAL DENSITOMETRY, 2013, 16 (02) : 250 - 256
  • [2] Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
    Keaveny, Tony M.
    McClung, Michael R.
    Genant, Harry K.
    Zanchetta, Jose R.
    Kendler, David
    Brown, Jacques P.
    Goemaere, Stefan
    Recknor, Chris
    Brandi, Maria L.
    Eastell, Richard
    Kopperdahl, David L.
    Engelke, Klaus
    Fuerst, Thomas
    Radcliffe, Hoi-Shen
    Libanati, Cesar
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (01) : 158 - 165
  • [3] Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture
    Simon, James A.
    Recknor, Christopher
    Moffett, Alfred H., Jr.
    Adachi, Jonathan D.
    Franek, Edward
    Lewiecki, E. Michael
    McClung, Michael R.
    Mautalen, Carlos A.
    Ragi-Eis, Sergio
    Nicholson, Geoffrey C.
    Muschitz, Christian
    Nuti, Ranuccio
    Torring, Ove
    Wang, Andrea
    Libanati, Cesar
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (02): : 130 - 137
  • [4] Denosumab, a RANK Ligand Inhibitor, for Postmenopausal Women with Osteoporosis
    Sutton, Emily E.
    Riche, Daniel M.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1000 - 1009
  • [5] Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
    Chen, Yi
    Zhu, Jun
    Zhou, Yiqin
    Peng, Jinhui
    Wang, Bo
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [6] Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
    Watts, N. B.
    Roux, C.
    Modlin, J. F.
    Brown, J. P.
    Daniels, A.
    Jackson, S.
    Smith, S.
    Zack, D. J.
    Zhou, L.
    Grauer, A.
    Ferrari, S.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (01) : 327 - 337
  • [7] Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
    Torring, Ove
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2015, 7 (03) : 88 - 102
  • [8] Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis
    McClung, M. R.
    Lippuner, K.
    Brandi, M. L.
    Zanchetta, J. R.
    Bone, H. G.
    Chapurlat, R.
    Hans, D.
    Wang, A.
    Zapalowski, C.
    Libanati, C.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (10) : 2967 - 2973
  • [9] Denosumab: an antifracture therapy for postmenopausal women with osteoporosis
    Jiang, Xuezhi
    Schnatz, Peter F.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (02): : 117 - 119
  • [10] Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
    Cummings, Steven R.
    San Martin, Javier
    McClung, Michael R.
    Siris, Ethel S.
    Eastell, Richard
    Reid, Ian R.
    Delmas, Pierre
    Zoog, Holly B.
    Austin, Matt
    Wang, Andrea
    Kutilek, Stepan
    Adami, Silvano
    Zanchetta, Jose
    Libanati, Cesar
    Siddhanti, Suresh
    Christiansen, Claus
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) : 756 - 765